Age-related hearing loss (ARHL) is a main acquired risk factor for dementia, including Alzheimer disease (AD), but links are unknown. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Age-related hearing loss (ARHL) is a main acquired risk factor for dementia, including Alzheimer disease (AD), but links are unknown. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Small palpebral fissure is an independent and previously unnoticed risk factor for glaucoma surgical failure, affecting both minimally invasive and filtration procedures. 3 key findings →
Participants: 339 Evidence: low
Full summary, score breakdown and related studies → Original source
The impact of age and hearing loss on the brain has garnered significant attention, as both factors have been implicated in the development of cognitive impairment or dementia. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source
Absolute BPV was associated with mortality, and DBP and MAP variability with overall stroke, after accounting for glycemic status and mean blood pressure. 5 key findings →
Design: prospective cohort Participants: 57,611 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Seasonally normalized 25(OH)D identifies a reproducible state of systemic vulnerability while reducing exposure misclassification caused by calendar timing of measurement. 5 key findings →
Design: longitudinal study Participants: 412,020 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Vascular dementia (VaD) is a leading cause of cognitive decline with no disease-modifying therapies. 2 key findings →
Participants: 437,749 Evidence: low
Full summary, score breakdown and related studies → Original source
Hypertension is associated with lower risk of dementia-related outcomes in aECAD patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We estimated associations per SD slower walking or smaller adaptability using linear, logistic, and Cox regression (10-year follow-up), overall and in women and men. 5 key findings →
Design: cross-sectional Participants: 2,308 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Newly diagnosed postoperative depression was associated with increased dementia risk, particularly in patients aged < 65 years, supporting prospective evaluation as a potential marker of long-term cognitive risk. 4 key findings →
Design: cohort study Participants: 424,637 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and Alzheimer's disease (AD) share several neuropathophysiological mechanisms, including axonal injury, neuroinflammation, and abnormal protein aggregation, which may contribute to overlapping clinical manifestations. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Wildfire smoke exposure is increasing across the U.S., but the long-term neurological effects of smoke-specific fine particulate matter (PM 2.5 ) and its carbonaceous components remain uncertain. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher UGS coverage was associated with a lower risk of incident AD among older adults in urban South Korea. 4 key findings →
Design: cohort study Participants: 95,822 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders, yet the environmental drivers that accelerate its progression remain poorly defined. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Higher exposure to PM 2.5 was associated with cerebral arteriolosclerosis and atherosclerosis at death, consistent with the known vascular toxicity of this pollutant. 5 key findings →
Design: cohort study Participants: 909 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Exposure to the highest quintile of PM 2·5 (Rte:1·14, 95% CI:1·06-1·23), NO x (Rte:1·11, 95% CI:1·03-1·20) or NO 2 (Rte:1·08, 95% CI:0·99-1·16), compared to the lowest quintile, was associated with higher dementia risk. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Ambient air pollution has been associated with increased incidence of chronic disease and is estimated to contribute towards 4.2 million early deaths annually. 2 key findings →
Participants: 22,071 Evidence: low
Full summary, score breakdown and related studies → Original source
Direct medical and productivity-related costs associated with incident cases were estimated using a cost-of-illness (COI) framework. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Middle East and North Africa (MENA) region represents the area of greatest projected growth in instances of Alzheimer’s disease and related dementias (ADRDs) globally, yet, it remains virtually uncharacterized in health studies of aging and ADRDs. 4 key findings →
Participants: 3,552 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 1,288,359 women, 20,070 with AUD were matched to 100,339 controls. 3 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
The 2,885 participants had a mean age of 69.5 years. 4 key findings →
Design: longitudinal study Participants: 2,885 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuroticism, a personality trait characterized by the predisposition to experience intense and frequent negative emotions, has been associated with an increased risk of Alzheimer’s disease (AD). 5 key findings →
Participants: 1,277 Evidence: low
Full summary, score breakdown and related studies → Original source
INTRODUCTIONLittle is understood about the extent to which lifestyle factors can advance or delay the risk of developing dementia, and whether that is dependent on non-modifiable factors, e.g. sex and genetic susceptibility.METHODSAmong 224,516 UK Biobank participants aged ≥50 years at baseline, Cox regression examined the relations of apolipoprotein E gene (APOE) genotypes, and lifestyle with incident dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Vascular risk factors were associated with CSVD burden and progression, and WMH and PVS progression were further associated with cortical atrophy and cognitive decline, underscoring the interconnected contributions of vascular risk, CSVD, and neurodegeneration to cognitive aging and dementia risk. 5 key findings →
Design: cross-sectional Participants: 289 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
In a contemporary, diverse cohort, most established dementia risk algorithms had limited power in discriminating amyloid positivity, pTau-217 positivity, and current cognitive status despite acceptable calibration. 3 key findings →
Participants: 603 Evidence: moderate
Full summary, score breakdown and related studies → Original source
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →